Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First‐in‐Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1354 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Masako Saito und 3 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma, Inc., Tokyo, Japan. Hauptthemen laut MEDLINE: Ureter, Indocyanine Green, Models, Biological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pudexacianinium (ASP5354) chloride is an indocyanine green derivative designed to enable enhanced ureter visualization during surgery. The objective of the present analysis was to determine appropriate doses of pudexacianinium for a phase 2, dose‐ranging study (NCT04238481). Real‐time urine pudexacianinium concentration is considered a good pharmacodynamic surrogate marker, since ureter visualization likely depends on its concentration in the ureter. Using plasma and urine concentrations of pudexacianinium from a phase 1 single‐ascending‐dose (0.1‐24.0 mg) study in healthy participants, a 3‐compartment population pharmacokinetic model with a urine output compartment was developed and effectively described the concentration‐time profiles. The individual estimated glomerular filtration rates had a significant impact on drug clearance. Simulations suggested that a 1.0 mg intravenous injection would achieve target urine concentrations over 1 μg/mL (determined from previous nonclinical studies) for 3 hours postdose, assuming a urine production rate of 1.0 mL/min. Based on this simulation, doses of 0.3, 1.0, and 3.0 mg were proposed for the phase 2 study. The observed plasma concentrations were generally consistent with model predictions. For urine, although only limited data could be obtained due to the difficulties of spot urine collection from surgical patients, intraoperative ureter visualization was successful at 1.0 and 3.0 mg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Astellas Pharma, Inc., Tokyo, Japan.
Zitieren
APA
Saito, M., Kojima, T., Komatsu, K., & Takusagawa, S. (2024). Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First‐in‐Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1354
Vancouver
Saito M, Kojima T, Komatsu K, Takusagawa S. Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First‐in‐Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1354
BibTeX
@article{Saito2024,
author = {Saito, Masako and Kojima, Tomoki and Komatsu, Kanji and Takusagawa, Shin},
title = {Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First‐in‐Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1354}
}
EUVIMED